Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
Phenotype
Lung cancer
398articles
398mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.
PMID 41373672 | PMCID PMC12692500 | DOI 10.3390/ijms262311517 · International journal of molecular sciences · 2025 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| phenotype | lung cancer | “Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | G12C | “This review highlights the evolving landscape of therapeutic strategies for actionable mutations in lung cancer, with particular attention given to the latest developments in KRAS-targeted treatments including non-G12C mutations, pan-RAS inhibitors, and agents targeting RAS-GTP.” | 0.82 | literature_variant_regex_v2 |
| gene | EGFR | “We also examine the existing standards of care for NSCLC harboring EGFR and ALK alterations, as well as emerging therapies poised for clinical use.” | 0.98 | hgnc_dict_v1 |
| gene | ROS1 | “Additional discussion includes advancements in therapies directed at MET, HER2, RET, ROS1, and FGFR alterations-each representing promising targets in NSCLC.” | 0.98 | hgnc_dict_v1 |
Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance.
PMID 40233529 | DOI 10.1016/j.prp.2025.155954 · Pathology, research and practice · 2025 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| phenotype | lung cancer | “Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | G12C | “In lung cancer, KRAS mutations, especially the G12C, favor aggressive tumor growth and resistance to standard therapies.” | 0.82 | literature_variant_regex_v2 |
| gene | KRAS | “In lung cancer, KRAS mutations, especially the G12C, favor aggressive tumor growth and resistance to standard therapies.” | 0.98 | hgnc_dict_v1 |